Pancreatic cancer has been one of the deadliest diseases, with over 90% of cases caused by RAS gene mutations. Until now, patients with advanced pancreatic cancer typically lived only six months after standard chemotherapy stopped working. However, a new daily pill called daraxonrasib has changed this reality.
In a major global trial, patients taking daraxonrasib lived a median of 13.2 months, compared to 6.7 months for those on standard chemotherapy. This means patients had roughly 60% lower risk of dying. The results were extremely significant from a scientific perspective.
Daraxonrasib, developed by Revolution Medicines in California, is the first drug of its kind to target RAS in its active state. Unlike previous RAS drugs that only worked against a rare mutation, daraxonrasib works against most pancreatic cancer mutations. It functions like "molecular glue," binding proteins and stopping cancer growth signals.
The drug was generally well tolerated, with common side effects including rash, mouth sores, and diarrhea. Early trials showed a disease control rate of about 90%, with 29% of patients experiencing significant tumor response.
The U.S. Food and Drug Administration has already granted the drug special designations to speed up approval. A first-line trial is already enrolling patients. For pancreatic cancer patients, this development offers new hope and extended survival possibilities.